I agree, As fond as I am of this company I find q4 unacceptable. I am listening to the call now and I do not hear a fire being lit to really go after it. It "feels" like they are willing to accept mediocrity.
They basically said 2021 is a regrouping year, and 1q21 will be similar to 4q20, so $5m-ish I guess. I take that to mean this isn't going anywhere this year.
We are at a point where if they are losing sales to chinese CBD junk, then maybe CVSI needs to add a chinese CBD junk entry level product under a different name and sell it cheap. This is common practice in other industries where if they can't beat them join them with a good/better/best strategy.